ClinicalTrials.gg
Sign In

Drug

Pegylated SN-38 Conjugate PLX038 clinical trials

Also written PLX 038.

studies test it
6
open now
1
in phase 3
0
first study started
2016

Keep track of what changes. Save the Pegylated SN-38 Conjugate PLX038 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Name

Pegylated SN-38 Conjugate PLX038
1

Development codes

PLX 038
3

Combined with it in one product

PLX038
4
PEGylated SN38
1
PLX038 + Tuvusertib
1

Studies by the year they started

6 studies that test it; most in 2024 (2)

Studies that test Pegylated SN-38 Conjugate PLX038, by start year
YearStudies
20161
20201
20221
20242
20251

By phase

A phase 1/2 study counts in both.

Phase 1
4
Phase 2
4

What it is tested for

Each study’s main condition, where its own words name it.

Fallopian Tube Neoplasms
1
Small Cell Lung Carcinoma
1
Glioma
1
Neoplasms
1

Who runs them

Industry 1 · Other 5

National Cancer Institute (NCI) (2) · Institut Curie (2) · Mayo Clinic (1) · ProLynx LLC (1)

Often tested with

Tested in the same studies.

DFP-13318 (5) · Rucaparib (1) · Tuvusertib (1)

Studies

Open first, then newest update. How each study uses Pegylated SN-38 Conjugate PLX038 is read from its arms, and is right about nine times in ten.

Testing it · 6